Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Public ClinicalTrials.gov record NCT03972488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Study identification
- NCT ID
- NCT03972488
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- 2.5% Lys-Arg sterile amino acid solution Drug
- 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) Drug
- High dose 60 mg octreotide long-acting repeatable Drug
- Lutathera Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2020
- Primary completion
- Jul 19, 2023
- Completion
- Oct 28, 2027
- Last update posted
- Jan 20, 2026
2020 – 2027
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| USF - H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| University of Iowa Hospitals and Clinics - Oncology | Iowa City | Iowa | 52242 | — |
| University of Kentucky UK Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| Mayo Clinic - Oncology | Rochester | Minnesota | 55905 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03972488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03972488 live on ClinicalTrials.gov.